Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefânia Neiva Lavorato has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors

    by Luiza V. Barreto, Estela M. G. Lourenço, Elany B. da Silva, Mariana O. de Godoy, Luan C. Martins, Mariana L. de Souza, Renata G. Almeida, Vitor L. S. Cunha, Magno C. Pires, Stefânia N. Lavorato, et al.

    Despite the development of vaccines and antivirals, coronavirus disease 2019 (COVID-19) continues to affect populations worldwide. Given the high mutation rate of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and reports of drug resistance, there is a continued need for new therapeutic options. SARS-CoV-2 main protease (Mpro) is essential for viral replication and is a conserved target among coronaviruses. Most known Mpro inhibitors target the active site, although allosteric sites have already been identified. In this study, a virtual screening of 2,060 compounds was conducted, targeting an allosteric site of SARS-CoV-2 Mpro. From this screen, 41 computational hits and analogs were selected and evaluated using biochemical assays against SARS-CoV-2 Mpro. Among them, compound 25, a semicarbazone, demonstrated a half-maximal inhibitory concentration (IC50) of 99 μM. Additionally, two thiosemicarbazone analogs (compounds 50 and 51) inhibited SARS-CoV-2 Mpro with IC50 values of 61 and 70 μM. Molecular dynamics simulations revealed that compound 25 is unstable at the allosteric site of SARS-CoV-2 Mpro but forms stable and favorable interactions at the active site, supporting its potential as a competitive inhibitor, a finding subsequently confirmed by biochemical assays. The structurebased computational and biochemical approach identified semicarbazone and thiosemicarbazone scaffolds as promising candidates for the development of reversible SARS-CoV-2 Mpro inhibitors.

  • Arylacetamides exhibit antiproliferative effects on non-transformed mammalian and vegetal cells and toxicity on crustaceans and fish embryos

    by Kátia da Conceição Machado, Jurandy Do Nascimento Silva, Débora Caroline Do Nascimento Rodrigues, Stefânia Neiva Lavorato, João Marcelo de Castro e Sousa, Ana Amélia de Carvalho Melo-Cavalcante, Patrícia Canteri de Souza, Paulo César Meletti, Diego Sousa Moura, José Roberto de Oliveira Ferreira, et al.

    Non-clinical steps for development, validation and biosafety of new medicines and products comprises studies on cells, proteins, and animals. Herein, we evaluated the toxic activity of antitumoral 2-chloro-N-arylacetamides on eukaryotic dividing cells and animal replacement models. Firstly, the cytotoxicity of chloro (compound 2), bromo (compound 3) and nitro (compound 4) acetamides was analyzed by fluorescent assays in fibroblasts. Next, toxicity was evaluated on Allium cepa meristematic cells and 48h-living Artemia salina larvae. Finally, embryos of Danio rerio (zebrafish) were exposed to the compound 2 (0.14 - 7.2 μg/mL) for 120 h exposure. All arylacetamides were cytotoxic on murine and human fibroblasts, with IC50 values ranging from 1.2 μg/mL (5.6 µM = compound 4 on L-929) to 4.9 μg/mL (24 µM = compound 2 on MRC-5 cells), respectively, and inhibited root growth from 10 to 100 µg/mL, corroborated by mitotic index reduction and cell cycle arrest in interphase (p < 0.05) without clastogenic injuries. Compound 2 showed time- and concentration-dependent killing effects on zebrafish embryos. Its 24 h-acute toxicity at higher concentrations (1.93 and 7.2 μg/mL with 90% and 100% death) corroborated toxicity on aquatic A. salina organisms. After 96 h exposure at 0.52 μg/mL (2.55 µM), almost 100% of the embryos showed more than one lethal/sublethal morphological abnormality (p < 0.05). Then, all arylacetamides showed unspecific toxic effects, mainly the halogenated electrophile chloroacetamide. They present strong antimitotic action on vertebrate and vegetal cells, although such antiproliferative activity does not seem to be directly related to chromosomal damage inductions.

  • Novel Synthesized Benzophenone Thiazole Hybrids Exhibited Ex Vivo and In Silico Anti‐Inflammatory Activity

    by Luiz Paulo Melchior de Oliveira Leão, Albert Katchborian Neto, Karen de Jesus Nicácio, Stefânia Neiva Lavorato, Fernanda Brito Leite, Karina Camargo Teixeira, Michael Murgu, Ana Cláudia Chagas de Paula, Marisi Gomes Soares, Daniela Aparecida Chagas‐Paula, et al.

    Novel benzophenone–thiazole hybrids with different substituents were synthesized and evaluated for anti‐inflammatory activity using an ex vivo human whole‐blood assay. All hybrids (3c and 5a–h) showed significant anti‐inflammatory activity via prostaglandin E2 (PGE2) release inhibition. Moreover, 5c (82.8% of PGE2 inhibition), 5e (83.1% of PGE2 inhibition), and 5h (82.1% of PGE2 inhibition) were comparable to the reference drugs. Molecular docking revealed potential preferable binding to the active sites of cyclooxygenase 2 (COX‐2) and microsomal prostaglandin E synthase‐1 (mPGES‐1) enzymes. This study provides the first evidence that benzophenone–thiazole hybrids may also dock in mPGES‐1, a new attractive anti‐inflammatory drug target, besides providing promising ex vivo anti‐inflammatory activity. Thus, the novel hybrids are promising anti‐inflammatory lead compounds and highlight the significance of optimal substituent selection in the design of potent PGE2 inhibitors.

  • Synthesis of new trypanocidal agents from the hybridisation of metronidazole and eugenol analogues

    by Mônica Fraccarolli Pelozo, Cleydson Finotti Cordeiro, Letícia Fonseca Inácio, Rayssa de Cassia Alves Lemini, Elda Gonçalves Souza e Leite, Monique Dias Benedetti, Cristiane Alves Tulha, Rômulo Dias Novaes, Ivo Santana Caldas, Diogo Teixeira Carvalho, et al.


  • Open Access

    Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence

    by Gustavo R. Villas-Boas, Stefânia N. Lavorato, Marina M. Paes, Pablinny M. G. de Carvalho, Vanessa C. Rescia, Mila S. Cunha, Manoel F. de Magalhães-Filho, Luis F. Ponsoni, Adryano Augustto Valladao de Carvalho, Roseli B. de Lacerda, et al.

    Serotonin (5-HT) receptors are found throughout central and peripheral nervous systems, mainly in brain regions involved in the neurobiology of anxiety and depression. 5-HT receptors are currently promising targets for discovering new drugs for treating disorders ranging from migraine to neuropsychiatric upsets, such as anxiety and depression. It is well described in the current literature that the brain expresses seven types of 5-HT receptors comprising eighteen distinct subtypes. In this article, we comprehensively reviewed 5-HT1-7 receptors. Of the eighteen 5-HT receptors known today, thirteen are G protein-coupled receptors (GPCRs) and represent targets for approximately 40% of drugs used in humans. Signaling pathways related to these receptors play a crucial role in neurodevelopment and can be modulated to develop effective therapies to treat anxiety and depression. This review presents the experimental evidence of the modulation of the “serotonergic receptosome” in the treatment of anxiety and depression, as well as demonstrating state-of-the-art research related to phytochemicals and these disorders. In addition, detailed aspects of the pharmacological mechanism of action of all currently known 5-HT receptor families were reviewed. From this review, it will be possible to direct the rational design of drugs towards new therapies that involve signaling via 5-HT receptors.


  • Open Access

    The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents

    by Gustavo R. Villas-Boas, Vanessa C. Rescia, Marina M. Paes, Stefânia N. Lavorato, Manoel F. de Magalhães-Filho, Mila S. Cunha, Rafael da C. Simões, Roseli B. de Lacerda, Renilson S. de Freitas-Júnior, Bruno H. da S. Ramos, et al.

    On March 11, 2020, the World Health Organization (WHO) officially declared the outbreak caused by the new coronavirus (SARS-CoV-2) a pandemic. The rapid spread of the disease surprised the scientific and medical community. Based on the latest reports, news, and scientific articles published, there is no doubt that the coronavirus has overloaded health systems globally. Practical actions against the recent emergence and rapid expansion of the SARS-CoV-2 require the development and use of tools for discovering new molecular anti-SARS-CoV-2 targets. Thus, this review presents bioinformatics and molecular modeling strategies that aim to assist in the discovery of potential anti-SARS-CoV-2 agents. Besides, we reviewed the relationship between SARS-CoV-2 and innate immunity, since understanding the structures involved in this infection can contribute to the development of new therapeutic targets. Bioinformatics is a technology that assists researchers in coping with diseases by investigating genetic sequencing and seeking structural models of potential molecular targets present in SARS-CoV2. The details provided in this review provide future points of consideration in the field of virology and medical sciences that will contribute to clarifying potential therapeutic targets for anti-SARS-CoV-2 and for understanding the molecular mechanisms responsible for the pathogenesis and virulence of SARS-CoV-2.


  • Violence against women and drug-facilitated sexual assault (DFSA): A review of the main drugs

    by Yanna Richelly de Souza Costa, Stefânia Neiva Lavorato, Julianna Joanna Carvalho Moraes de Campos Baldin